EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?

Sepideh Gholami; Axel Grothey

doi:10.1016/S1470-2045(20)30003-6

EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?

Sepideh Gholami, Axel Grothey

Surgery

Research output: Contribution to journal › Comment/debate › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	324-326
Number of pages	3
Journal	The Lancet Oncology
Volume	21
Issue number	3
DOIs	https://doi.org/10.1016/S1470-2045(20)30003-6
State	Published - Mar 2020

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/S1470-2045(20)30003-6

Cite this

@article{f6b323eae0ad43ee88ab372fe5fcc4f4,

title = "EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?",

author = "Sepideh Gholami and Axel Grothey",

year = "2020",

month = mar,

doi = "10.1016/S1470-2045(20)30003-6",

language = "English (US)",

volume = "21",

pages = "324--326",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "3",

}

TY - JOUR

T1 - EGFR antibodies in resectable metastatic colorectal liver metastasis

T2 - more harm than benefit?

AU - Gholami, Sepideh

AU - Grothey, Axel

PY - 2020/3

Y1 - 2020/3

UR - http://www.scopus.com/inward/record.url?scp=85080094645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85080094645&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(20)30003-6

DO - 10.1016/S1470-2045(20)30003-6

M3 - Comment/debate

C2 - 32014120

AN - SCOPUS:85080094645

VL - 21

SP - 324

EP - 326

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 3

ER -

EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this